logo

Emergent Biosolutions Inc (EBS)



Trade EBS now with
  Date
  Headline
1/9/2023 8:26:45 AM Emergent BioSolutions Now Sees FY Total Revenues Of $1.1-$1.12 Bln; To Reduce 5% Of Workforce
9/6/2022 6:35:32 AM Emergent BioSolutions Initiates Phase 1 Study Of Lassa Virus Vaccine Candidate
6/24/2022 6:34:23 AM Emergent BioSolutions: FDA Accepts For Review The BLA For AV7909 Anthrax Vaccine Candidate
5/16/2022 6:49:11 AM Emergent BioSolutions To Acquire Chimerix's Exclusive Worldwide Rights To TEMBEXA
3/11/2022 6:40:56 AM Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment For Cyanide Poisoning
1/14/2022 6:42:27 AM Emergent BioSolutions Says Fuad El-Hibri, Founder And Executive Chairman, Will Retire Effective April 1, 2022
12/16/2021 7:36:46 AM Emergent BioSolutions Doses First Patient In Phase 1 Study Of Universal Influenza Vaccine Candidate
10/15/2021 6:45:52 AM Emergent BioSolutions Begins Phase 3 Study Of Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
1/25/2021 8:53:50 AM Emergent, Humanigen Enter Contract Development And Manufacturing Services Agreement For Lenzilumab
8/7/2014 7:34:24 PM Emergent BioSolutions Inc (EBS) Has Raised Its 2014 Revenue Estimate To $425 - $450 Mln From $415 - $445 Mln